Study on multicenter open-label randomized clinical trial of favipiravir to evaluate the viral load reduction effect in asymptomatic and mild patients with SARS-CoV2 infection/A multicenter observational study to evaluate the clinical course of moderate and severe patients receiving favipiravir

Favipiravir is an antiviral drug created by Toyama Chemical Co., Ltd. (Fujifilm Toyama Chemical Co., Ltd.) It was approved by the Ministry of Health, Labor and Welfare in March 2014, limiting the indications and effects to "emerging or re-emerging influenza virus infections (only if other anti-influenza virus drugs are ineffective or insufficiently effective)." The mechanism of action is that triphosphorylated form (T-705RTP) converted in vivo selectively inhibits viral RNA polymerase, so it is expected to be effective against RNA viruses other than influenza virus, but there is no evidence of utility for SARS-CoV2 infection. The aim of this research is to clarify the usefulness of favipiravir for asymptomatic and mild patients with SARS-CoV2 infection and the clinical course of moderate and severe patients receiving favipiravir by Specified Clinical Research